Clinical Trials
153 trialsPembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
City of Hope Medical Center
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
M.D. Anderson Cancer Center
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Bristol-Myers Squibb
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
Sanofi
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
University of California, Davis
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma
Alaunos Therapeutics
ConsortiumIO
Vedanta Biosciences, Inc.
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Eisai Inc.
High-Risk Skin Cancers With Atezolizumab Plus NT-I7
NeoImmuneTech
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
Anaveon AG
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Incyte Corporation
GLIMMER-01
Palleon Pharmaceuticals, Inc.
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
MGC018 With or Without MGA012 in Advanced Solid Tumors
MacroGenics
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)
Hoffmann-La Roche
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
Roswell Park Cancer Institute
Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma
Mayo Clinic
RTA 408 Capsules in Patients With Melanoma - REVEAL
Biogen
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
NGM Biopharmaceuticals, Inc
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
Mural Oncology, Inc
CONTRAC
Dana-Farber Cancer Institute
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Kymab Limited
Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)
Syndax Pharmaceuticals
Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis
LEO Pharma
ATL001 in Patients With Metastatic or Recurrent Melanoma
Achilles Therapeutics UK Limited
A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis
LEO Pharma
Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis
LEO Pharma
Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
LEO Pharma
Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
Fred Hutchinson Cancer Center
Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma
Herlev Hospital
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
Sarcoma Oncology Research Center, LLC
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
National Cancer Institute (NCI)
MODULATE
Immodulon Therapeutics Ltd
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
National Cancer Institute (NCI)
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
M.D. Anderson Cancer Center
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
University of Colorado, Denver
A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma
Lokon Pharma AB
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
GlaxoSmithKline
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
Columbia University
MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
Dana-Farber Cancer Institute
JAVELIN Medley
Pfizer
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
Haihe Biopharma Co., Ltd.
LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Dana-Farber Cancer Institute
QUAD01
University of Pittsburgh
Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma
Amgen
Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.
Elios Therapeutics, LLC
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.